Provided by Tiger Trade Technology Pte. Ltd.

Goldman Sachs Future Health Care Equity ETF

37.67
0.0000
Volume:1
Turnover:37.90
Market Cap:19.78M
PE:- -
High:37.67
Open:37.67
Low:37.67
Close:37.67
52wk High:38.66
52wk Low:31.32
Shares:525.00K
Float Shares:525.00K
Volume Ratio:0.00
T/O Rate:0.00%
Dividend:0.11
Dividend Rate:0.30%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Johnson & Johnson Schedules Investor Call to Discuss Third-Quarter Results

Reuters
·
Sep 01

Dow Jones Top Company Headlines at 5 PM ET: FTC Files Lawsuit Alleging Amazon Deceived Advertisers | State ...

Dow Jones
·
Sep 01

Ataibeckley - Hart-Scott-Rodino Waiting Period for Merger with Eli Lilly Expired on Aug 28, 2026 - SEC Filing

THOMSON REUTERS
·
Sep 01

NeuroThera Labs Advances Enrollment in Autism Drug Trial for SCI-210

TIPRANKS
·
Sep 01

SciSparc subsidiary provides update on SCI-210 trial enrollment

TIPRANKS
·
Sep 01

PMV Pharmaceuticals announces updated ovarian cancer data from PYNNACLE trial

TIPRANKS
·
Sep 01

Kestra Medical Technologies to Report First Quarter Fiscal 2027 Financial Results on September 14

GlobeNewswire
·
Sep 01

Press Release: Kestra Medical Technologies to Report First Quarter Fiscal 2027 Financial Results on September 14

Dow Jones
·
Sep 01

Sector Update: Healthcare Stocks Decline Monday Afternoon

MT Newswires Live
·
Sep 01

Moderately bullish activity in Eli Lilly with shares down 1.26%

TIPRANKS
·
Sep 01

Top Midday Stories: Stocks Fall, Oil Rises Amid Renewed Fighting in Middle East; Utility Shares Fall After California Wildfire Legislation

MT Newswires Live
·
Aug 31

Protagonist Therapeutics' Own Pipeline Seen as Main Long-Term Growth Driver, Wedbush Says

MT Newswires Live
·
Aug 31

Dow Jones Top Company Headlines at 11 am ET: GameStop Sees Higher Profit as eBay Investment Offsets Lower Sales | SLB ...

Dow Jones
·
Aug 31

Lilly is Bigger than Ever. Why Its Latest $2.9 Billion Immunology Deal Makes Sense.

Dow Jones
·
Aug 31

Eli Lilly's Psoriasis Drug Trial Shows Sustained Positive Results

Dow Jones
·
Aug 31

Acotec Swings to Loss on R&D Surge and U.S. Trial Impairment

TIPRANKS
·
Aug 31

Lilly to Buy This Autoimmune Drugmaker for $2.9 Billion in Cash. What it Means for the Stock.

Dow Jones
·
Aug 31

Eli Lilly announces 52-week results from TOGETHER-PsO, TOGETHER-PsA

TIPRANKS
·
Aug 31

Eli Lilly - Taltz and Zepbound Lead to Deeper Improvements in Systemic Inflammation in Both Trials

THOMSON REUTERS
·
Aug 31

New Phase 3B Data on Lilly's Taltz (Ixekizumab) and Zepbound (Tirzepatide) Used Together Showed Improved and Durable Efficacy at One Year in Adults with Psoriatic Disease and Obesity

THOMSON REUTERS
·
Aug 31